on TRANSGENE (EPA:TNG)
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Strasbourg, France, September 10, 2024 – Transgene, a biotech company focused on virus-based immunotherapies for cancer treatment, has appointed Dr. Emmanuelle Dochy as Chief Medical Officer (CMO) and Dr. Maurizio Ceppi as Chief Scientific Officer (CSO). Both are experts in advancing cancer immunotherapies and precision medicine.
Dr. Dochy, with over 15 years in the pharmaceutical industry, previously worked at Bayer and Sanofi, where she held senior roles. She will oversee Transgene’s clinical development, including the TG4050 cancer vaccine.
Dr. Ceppi also brings 15 years of experience in oncology. He has worked with Roche and iTeos Therapeutics, specializing in cancer immunotherapy and precision medicine. At Transgene, he will lead scientific innovation, focusing on novel immunotherapies.
These appointments come as Transgene advances its innovative therapeutic programs, aiming to deliver new cancer treatments to patients.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news